We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AMN Healthcare Services, Inc. (AMN - Free Report) announced preliminary financial results for fourth-quarter 2021 on Jan 10. Following this release, shares of the company are down 0.7% till the last trading.
The company is expected to release the Q4 and 2021 results in February.
Prelim Q4 in Detail
As per the preliminary report, fourth-quarter revenues are likely to be $1.35-$1.36 billion. The Zacks Consensus Estimate of $1.22 billion remains below the preliminary figure.
AMN Healthcare’s preliminary revenue projection for the fourth quarter exceeds its earlier-provided expectation of $1,130-$1,150 million, issued in its third-quarter financial results on Nov 4, 2021. Per the company, this revenue surge resulted primarily from strong demand across all revenue segments (led by the Nurse and Allied segment) and around an additional $70 million of labor disruption revenues than included in the earlier-provided guidance.
Q1 FY22 Guidance
Per management, the persistent healthcare labor shortages are expected to persist for some time. This highlights the need for short- and long-term workforce solutions, leading to wage inflation. These influences were even more substantial than expected in the fourth quarter of 2021 and are also expected to continue into 2022.
Management expects first-quarter 2022 revenues to be more than $1.1 billion on the back of continued robust demand for all of its talent solutions. The Zacks Consensus Estimate of $1.11 billion is slightly above the company’s projections.
Our Take
AMN Healthcare’s impressive preliminary fourth-quarter performance projections raise our optimism. Continued strength in the company’s staffing services and a broad array of other services are impressive. Persistent workforce shortages and growing patient volumes have been robustly contributing to AMN Healthcare’s revenues, a trend which is expected to have continued in the to-be-reported quarter. This looks promising for the stock.
Price Performance
Shares of the company have gained 6.4% between October and December 2021 against the industry’s 15.8% fall. The S&P 500 has risen 8.9% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, AMN Healthcare flaunts a Zacks Rank #1 (Strong Buy).
A few other stocks from the broader medical space that investors can consider are Henry Schein, Inc. (HSIC - Free Report) , Cerner Corporation and Catalent, Inc. (CTLT - Free Report) .
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 21.86%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Henry Schein has lost 1.3% against the industry’s 4.5% rise between October and December 2021.
Cerner, carrying a Zacks Rank #2, has an estimated long-term growth rate of 13.3%. CERN’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 3.21%.
Cerner has gained 32% against the industry’s 3.7% fall between October and December 2021.
Catalent has an estimated long-term growth rate of 16.9%. CTLT’s earnings surpassed estimates in the trailing four quarters, the average surprise being 9.88%. It currently sports a Zacks Rank #1.
Catalent has lost 2.9% compared with the industry’s 4.1% fall between October and December 2021.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
AMN Healthcare (AMN) Reports Solid Preliminary Q4 Revenues
AMN Healthcare Services, Inc. (AMN - Free Report) announced preliminary financial results for fourth-quarter 2021 on Jan 10. Following this release, shares of the company are down 0.7% till the last trading.
The company is expected to release the Q4 and 2021 results in February.
Prelim Q4 in Detail
As per the preliminary report, fourth-quarter revenues are likely to be $1.35-$1.36 billion. The Zacks Consensus Estimate of $1.22 billion remains below the preliminary figure.
AMN Healthcare’s preliminary revenue projection for the fourth quarter exceeds its earlier-provided expectation of $1,130-$1,150 million, issued in its third-quarter financial results on Nov 4, 2021. Per the company, this revenue surge resulted primarily from strong demand across all revenue segments (led by the Nurse and Allied segment) and around an additional $70 million of labor disruption revenues than included in the earlier-provided guidance.
Q1 FY22 Guidance
Per management, the persistent healthcare labor shortages are expected to persist for some time. This highlights the need for short- and long-term workforce solutions, leading to wage inflation. These influences were even more substantial than expected in the fourth quarter of 2021 and are also expected to continue into 2022.
Management expects first-quarter 2022 revenues to be more than $1.1 billion on the back of continued robust demand for all of its talent solutions. The Zacks Consensus Estimate of $1.11 billion is slightly above the company’s projections.
Our Take
AMN Healthcare’s impressive preliminary fourth-quarter performance projections raise our optimism. Continued strength in the company’s staffing services and a broad array of other services are impressive. Persistent workforce shortages and growing patient volumes have been robustly contributing to AMN Healthcare’s revenues, a trend which is expected to have continued in the to-be-reported quarter. This looks promising for the stock.
Price Performance
Shares of the company have gained 6.4% between October and December 2021 against the industry’s 15.8% fall. The S&P 500 has risen 8.9% in the same time frame.
Zacks Rank & Other Key Picks
Currently, AMN Healthcare flaunts a Zacks Rank #1 (Strong Buy).
A few other stocks from the broader medical space that investors can consider are Henry Schein, Inc. (HSIC - Free Report) , Cerner Corporation and Catalent, Inc. (CTLT - Free Report) .
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 21.86%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Henry Schein has lost 1.3% against the industry’s 4.5% rise between October and December 2021.
Cerner, carrying a Zacks Rank #2, has an estimated long-term growth rate of 13.3%. CERN’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 3.21%.
Cerner has gained 32% against the industry’s 3.7% fall between October and December 2021.
Catalent has an estimated long-term growth rate of 16.9%. CTLT’s earnings surpassed estimates in the trailing four quarters, the average surprise being 9.88%. It currently sports a Zacks Rank #1.
Catalent has lost 2.9% compared with the industry’s 4.1% fall between October and December 2021.